Using electronic patient-reported measures to characterize symptoms and improvement in inpatient psychiatric units.
Anxiety
Assessment
Depression
Inpatient
Self-report
Suicide
Journal
Psychiatry research
ISSN: 1872-7123
Titre abrégé: Psychiatry Res
Pays: Ireland
ID NLM: 7911385
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
03
03
2022
revised:
30
08
2022
accepted:
07
09
2022
pubmed:
19
9
2022
medline:
18
11
2022
entrez:
18
9
2022
Statut:
ppublish
Résumé
Patient-reported measures are an important tool in personalizing care and monitoring clinical outcomes. This work presents results from the routine collection of self-report measures from individuals (n = 753) admitted to depression and anxiety inpatient units at McLean Hospital. 93.7% participated in the Clinical Measurement Initiative (CMI) between September 2020 and February 2022 on the most established unit. The average time between admission and discharge measures was 12.6 days and an attrition rate of 10.4% was observed on this unit. Missingness of discharge assessments was unrelated to symptom severity or comorbidities. We discuss the feasibility of deploying patient-reported measures as part of routine care in an inpatient psychiatric setting. Systematic evaluation of potential treatment modifiers (e.g., personality disorder, trauma history, and substance misuse) may be valuable in better serving those impacted by psychiatric illness.
Identifiants
pubmed: 36116185
pii: S0165-1781(22)00432-2
doi: 10.1016/j.psychres.2022.114839
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
114839Informations de copyright
Copyright © 2022. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Dr. Ressler reports having performed scientific consultation for Bioxcel, Bionomics, Acer, Takeda, and Jazz Pharmaceuticals. He serves on Scientific Advisory Boards for Sage Therapeutics and the Brain Research Foundation, and he has received sponsored research support from Takeda, Brainsway and Alto Neuroscience. None of these roles are related to the current publication.